Back to Search
Start Over
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial
- Source :
- Am J Hematol
- Publication Year :
- 2018
- Publisher :
- Wiley, 2018.
-
Abstract
- Ibrutinib demonstrated superior response rates and survival for treatment-naïve chronic lymphocytic leukemia (CLL) patients in a pivotal study that excluded patients younger than 65 (
- Subjects :
- Male
medicine.medical_specialty
Population
Article
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Piperidines
Internal medicine
medicine
Humans
education
Survival analysis
Aged
Retrospective Studies
Sequence Deletion
Clinical Trials as Topic
education.field_of_study
business.industry
Adenine
Remission Induction
Age Factors
Retrospective cohort study
Hematology
Middle Aged
Leukemia, Lymphocytic, Chronic, B-Cell
Survival Analysis
Rash
Discontinuation
Clinical trial
Pyrimidines
Treatment Outcome
chemistry
030220 oncology & carcinogenesis
Ibrutinib
Cohort
Pyrazoles
Female
medicine.symptom
business
Chromosomes, Human, Pair 17
030215 immunology
Subjects
Details
- ISSN :
- 03618609
- Volume :
- 93
- Database :
- OpenAIRE
- Journal :
- American Journal of Hematology
- Accession number :
- edsair.doi.dedup.....ca9f0b2ab0c356e3f1536fcc104b3970